Evaluation of antioxidant and antimicrobial properties of the Angolan Cymbopogon Citratus essential oil with a view to its utilization as food biopreservative

It was studied the chemical composition, antioxidant, antibacterial and antifungal properties of the essential oil obtained from the Cymbopogon citratus of Angolan origin. Its major constituents analyzed by GC-MS were α-citral (40.55%), β-citral (28.26%), myrcene (10.50%) and geraniol (3.37%). The essential oil antioxidant capacity was statistically identical to that of synthetic antioxidants (DPPH IC50 of 41.7 μg/ml) and superior to that of extracts obtained from fresh leaves of the plant (DPPH IC50 of 55.7 μg/ml). The oil also demonstrated to possess high antibacterial activity even against multidrug resistant strains of Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae and antifungal activity against Candida albicans and Non-Candida albicans, Candida parapsilosis and Candida tropicalis. The results of this study, in conjunction with already published data on the properties of other Cymbopogon citratus oils, provide evidence that it could have a potential application as food preservative.info:eu-repo/semantics/publishedVersio

Cymbopogon citratus EO antimicrobial activity against multi-drug resistant Gram-positive strains and non-albicans-Candida species

We studied the antibacterial and antifungal activity of Cymbopogon citratus. These properties were studied on hospital isolated multidrug resistant strains Staphylococcus aureus, Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Klebsiella pneumonia and their respective ATCC control strains. Pathogenic Candida albicans, Candida parapsilosis, and Candida tropicalis were also tested. Results of the present investigation provide evidence that the EO of Cymbopogon citratus could have a potential application in the treatment and prevention of diseases caused by Staphylococcus aureus methicillin-resistant strains and by vancomicin-resistant Staphylococcus epidermidis. Cymbopogon citratus EO is also effective against Candida albicans as well as the emerging Candida parapsilosis and Candida tropicalis pointing to its usefulness as an antifungal agent.info:eu-repo/semantics/publishedVersio

Narrando viagens e invenções. Hercule Florence: amigo das artes na periferia do capitalismo

O volumoso manuscrito de 423 páginas redigido entre 1837 e 1859, por Antoine Hercule Romuald Florence (1804-1879), intitulado L'ami des arts livré à lui-même. Recherche et découvertes sur différents sujets nouveaux, traz uma compilação dos principais objetos de estudo e reflexão desse franco-monegasco radicado no Brasil. Neste artigo, o L'ami des arts é compreendido como ponto de partida para uma contextualização das pesquisas que resultaram na invenção da photographie, método de reprodução de textos e desenhos anunciado na Província de São Paulo em 1834. Em seguida, a leitura do relato da Expedição Langsdorff apresentado no mesmo manuscrito foi, por sua vez, o ponto de partida para estabelecer uma classificação das diferentes versões escritas por Florence. A partir da pesquisa em suas correspondências ativas foi ainda possível recuperar o esforço do autor para publicar a conhecida narrativa de Viagem Fluvial. De modo geral, busca-se, aqui, problematizar a cronologia de suas invenções e das versões de seu relato da expedição Langsdorff, mostrando as intersecções entre as narrativas das invenções e das viagens, em especial o cruzamento fixado na matriz autobiográfica

Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil

Introduction and objectives: Direct antiviral agents (DAAs) including sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM) and ombitasvir, paritaprevir and dasabuvir were introduced 2015 in Brazil for treatment of hepatitis C virus (HCV) infection. The aims of this study were to assess effectiveness and safety of HCV treatment with DAA in real-life world in a highly admixed population from Brazil. Materials and methods: All Brazilian reference centers for HCV treatment were invited to take part in a web-based registry, prospectively conducted by the Brazilian Society of Hepatology, to assess outcomes of HCV treatment in Brazil with DAAs. Data to be collected included demographics, disease severity and comorbidities, genotype (GT), viral load, DAA regimens, treatment side effects and sustained virological response (SVR). Results: 3939 patients (60% males, mean age 58 ± 10 years) throughout the country were evaluated. Most had advanced fibrosis or cirrhosis, GT1 and were treated with SOF/DCV or SOF/SIM. Overall SVR rates were higher than 95%. Subjects with decompensated cirrhosis, GT2 and GT3 have lower SVR rates of 85%, 90% and 91%, respectively. Cirrhosis and decompensated cirrhosis in GT1 and male sex and decompensated cirrhosis in GT3 were significantly associated with no SVR. Adverse events (AD) and serious AD occurred in 18% and 5% of those subjects, respectively, but less than 1% of patients required treatment discontinuation. Conclusion: SOF-based DAA regimens are effective and safe in the heterogeneous highly admixed Brazilian population and could remain an option for HCV treatment at least in low-income countries

Geoeconomic variations in epidemiology, ventilation management, and outcomes in invasively ventilated intensive care unit patients without acute respiratory distress syndrome: a pooled analysis of four observational studies

Background: Geoeconomic variations in epidemiology, the practice of ventilation, and outcome in invasively ventilated intensive care unit (ICU) patients without acute respiratory distress syndrome (ARDS) remain unexplored. In this analysis we aim to address these gaps using individual patient data of four large observational studies. Methods: In this pooled analysis we harmonised individual patient data from the ERICC, LUNG SAFE, PRoVENT, and PRoVENT-iMiC prospective observational studies, which were conducted from June, 2011, to December, 2018, in 534 ICUs in 54 countries. We used the 2016 World Bank classification to define two geoeconomic regions: middle-income countries (MICs) and high-income countries (HICs). ARDS was defined according to the Berlin criteria. Descriptive statistics were used to compare patients in MICs versus HICs. The primary outcome was the use of low tidal volume ventilation (LTVV) for the first 3 days of mechanical ventilation. Secondary outcomes were key ventilation parameters (tidal volume size, positive end-expiratory pressure, fraction of inspired oxygen, peak pressure, plateau pressure, driving pressure, and respiratory rate), patient characteristics, the risk for and actual development of acute respiratory distress syndrome after the first day of ventilation, duration of ventilation, ICU length of stay, and ICU mortality. Findings: Of the 7608 patients included in the original studies, this analysis included 3852 patients without ARDS, of whom 2345 were from MICs and 1507 were from HICs. Patients in MICs were younger, shorter and with a slightly lower body-mass index, more often had diabetes and active cancer, but less often chronic obstructive pulmonary disease and heart failure than patients from HICs. Sequential organ failure assessment scores were similar in MICs and HICs. Use of LTVV in MICs and HICs was comparable (42·4% vs 44·2%; absolute difference -1·69 [-9·58 to 6·11] p=0·67; data available in 3174 [82%] of 3852 patients). The median applied positive end expiratory pressure was lower in MICs than in HICs (5 [IQR 5-8] vs 6 [5-8] cm H2O; p=0·0011). ICU mortality was higher in MICs than in HICs (30·5% vs 19·9%; p=0·0004; adjusted effect 16·41% [95% CI 9·52-23·52]; p<0·0001) and was inversely associated with gross domestic product (adjusted odds ratio for a US$10 000 increase per capita 0·80 [95% CI 0·75-0·86]; p<0·0001). Interpretation: Despite similar disease severity and ventilation management, ICU mortality in patients without ARDS is higher in MICs than in HICs, with a strong association with country-level economic status

Núcleos de Ensino da Unesp: artigos 2007

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq